Nanocap biotech Viracta Therapeutics (NASDAQ:VIRX) added ~20% premarket Wednesday after the company announced a corporate shake-up to prioritize its Epstein-Barr virus-positive (EBV+) lymphoma program...
Source LinkNanocap biotech Viracta Therapeutics (NASDAQ:VIRX) added ~20% premarket Wednesday after the company announced a corporate shake-up to prioritize its Epstein-Barr virus-positive (EBV+) lymphoma program...
Source Link
Comments